Metastatic castration‐resistant prostate cancer (mCRPC) is an ultimately progress stage of prostate cancer (PC) that is associated with short survival and a poor prognosis.1 Androgen deprivation therapy (ADT) prevents PC cell proliferation by cutting off androgen receptor (AR) signaling. The gene discussed is AR; the disease is pachyonychia congenita.